The present invention generally relates to the transdermal delivery of various compounds. In some aspects transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising a phosphodiesterase type 5 inhibitor and/or a salt thereof and optionally a hostile biophysical environment and/or a nitric oxide donor. In some cases the composition may be stabilized using a combination of a stabilization pol...

The invention provides methods of treating nitric oxide/cGMP pathway-cell adhesion disorders and related pharmaceutical compositions diagnostics screening techniques and kits. In one embodiment the invention relates to a method for down-regulating ?4?1-integrin affinity and inhibiting and reversing adhesion formation in patients or subjects in need using a nitric oxide donor.

A novel process for preparing thiazolidinediones preferably Pioglitazone as described. Also described are novel intermediates involved in its synthesis and process for their preparation and use in medicine.

The present invention describes pharmaceutical compositions that comprise a tacrolimus powder for oral suspension that exhibits great stability as a powder for suspension and also once prepared as the extemporaneous suspension without the formation of cake-like clusters same having a satisfactory flavour and a pleasant aroma. The invention also describes the method for preparing the pharmaceutical compositions same being a dry method that comprises mixing tacrolimus and presieved pharmaceuticall...

Formulations of cross-linkable polymers capable of forming non-toxic and biocompatible hydrogels in situ containing at least one of doxycycline or minocycline. Methods of using the hydrogels for treating the skin or ocular tissues of mammals exposed to vesicant compounds such as sulfur mustard (SM) nitrogen mustard (NM) or half mustard (2-chloroethyl ethyl sulfide (CEES)) are also disclosed.

The invention features methods compositions and infusion pumps for infusing levodopa prodrugs (e.g. levodopa esters levodopa amides levodopa carboxamides and levodopa sulfonamides) for the treatment of Parkinson's disease.

There is described (S)-(+)-2-(2-fluoro-4-biphenylyl) propionic acid, or a salt or ester thereof, having substantially limited amounts of specific impurities associated with the synthesis and purification of the (S)-(+)-2-(2-fluoro-4-biphenylyl) propionic acid.

The present invention provides a compound of formula I

The instant invention relates to novel solid materials of {[(2S,5R,8S,11S)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid}, methods for producing them, and the use of said solid materials in pharmaceuticals.

The present invention provides indane acetic acid and their derivatives and methods for the treating and/or preventing of Alzheimer's diseases.